



Updated Monthly

January 10, 2023

---

THE ESSENTIAL GUIDE TO

# Non-Dilutive Government Funding

Published by:



## Questions?

Liz Powell, Esq., MPH

[lpowell@G2Gconsulting.com](mailto:lpowell@G2Gconsulting.com)

[www.G2Gconsulting.com](http://www.G2Gconsulting.com)



@G2Gconsulting



## TABLE OF CONTENTS

### New Opportunities

Aging.....	2
Amyotrophic Lateral Sclerosis .....	2
Autoimmune diseases .....	3
Biotechnology and Biomanufacturing.....	3
Cancer .....	4
Central Nervous System .....	6
Cognitive and Brain Health.....	6
Communication Disorders .....	7
Coronavirus .....	7
Endocrine and Metabolic Diseases .....	8
Genomics .....	8
Health IT .....	8
HIV/AIDS .....	11
Immunology & Infectious Disease .....	11
Maternal and Pediatric Health .....	12
Mental Health.....	12
Musculoskeletal Health .....	13
Patient-Centered Research .....	14

### New Opportunities

Reconstructive Transplant .....	15
Regenerative Medicine.....	15
Research Resources.....	15
Substance Use Disorder .....	15
Therapeutics.....	16
Tuberous Sclerosis Complex .....	16

### Recurring Opportunities

Air Force .....	17
Army.....	18
BARDA .....	20
DARPA .....	20
Defense Threat Reduction Agency .....	21
Department of Energy .....	21
National Science Foundation .....	21
Navy .....	22



**January 20, 2023** – Join us for G2G’s Monthly [Non-Dilutive Funding: GBG Reporting Service Webinar](#) at 10-10:30am EST (FREE and open to all) then from 10:30-11am EST (premium service and private consultation for G2G and GBG customers). **We have a [NEW link](#) for 2023 so be sure to [register](#) to use it each month. The old link will no longer work.**

**MHSRS Call for Abstracts** is open through February 19, 2023. Join G2G on **January 31, 2023 at 12:00pm EST** for insights into successfully submitting an abstract and tips on navigating and engaging with DoD and other government funding collaborators. [Register here.](#)

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>AGING (2)</b>		
1.	Prevention, Early Identification, and Treatment of Delirium in Older Adults -- Cycle 1 2023 (PCORI)	PCORI’s Targeted PFA will solicit applications for CER studies that focus on one or more of three research areas within delirium research: Prevention; Early Identification; Treatment. These three research areas encompass real-world challenges within delirium research. <a href="https://www.pcori.org/funding-opportunities/announcement/prevention-early-identification-and-treatment-delirium-older-adults-targeted-pfa-cycle-1-2023">https://www.pcori.org/funding-opportunities/announcement/prevention-early-identification-and-treatment-delirium-older-adults-targeted-pfa-cycle-1-2023</a>	Up to \$10 million, for up to 5 years	Letter of intent: 2/7/23 Proposal: 5/2/23
2.	Interorgan Communication in Aging (U01 Clinical Trial Not Allowed) (NIH/NIA)  RFA-AG-24-005	This FOA invites applications to examine the molecular mechanisms and consequences of age-related alterations in interorgan communication. Elucidation of the mechanisms that modulate and coordinate organ interactions, and their changes with age, may provide new insights into multimorbidities. <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-24-005.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-24-005.html</a>	Up to \$400,000 per year, for up to 4 years	Letter of intent: 4/1/23 Proposal: 6/1/23
		<b>AMYOTROPHIC LATERAL SCLEROSIS (5)</b>		
3.	Pre-Announcement: FY23 Amyotrophic Lateral Sclerosis Research Program (DoD/CDMRP)	The FY23 Defense Appropriations Act is anticipated to provide funding for the ALSRP to support development of effective treatments for amyotrophic lateral sclerosis (ALS). Four awards are anticipated: Pilot Clinical Trial Award, Therapeutic Development Award, Clinical Biomarker Development Award, Therapeutic Idea Award. <a href="https://cdmrp.health.mil/pubs/press/2023/23alsrppreann">https://cdmrp.health.mil/pubs/press/2023/23alsrppreann</a>	Up to \$2 million, for up to 4 years Dependent upon award mechanism	TBD

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>AMYOTROPHIC LATERAL SCLEROSIS</b>		
4.	Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required) (NIH/NINDS/OD)  RFA-NS-23-012	This FOA encourages grant applications for the conduct of scientific research utilizing data from expanded access (EA) for investigational drugs or biological products. These applications will target EA for intermediate size populations of patients living with amyotrophic lateral sclerosis (ALS) who are not eligible for ongoing clinical trials for the prevention, diagnosis, mitigation, treatment, or cure of ALS.  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-23-012.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-23-012.html</a>	Dependent upon proposal, for up to 4 years	Letter of intent: 2/23/23 Proposal: 3/23/23
		<b>AUTOIMMUNE DISEASES (2)</b>		
5.	Autoimmunity Centers of Excellence, Basic/Clinical Research Program (U19/UM1 Clinical Trial Not Allowed/Required) (NIH/NIAID)  RFA-AI-22-070 (U19) RFA-AI-22-071 (UM1)	The members of the Basic and Clinical ACE will work together after award to design, develop, and conduct studies of autoimmunity and autoimmune diseases in humans. This approach is expected to advance our fundamental understanding of human autoimmunity, identify common and distinct mechanisms in the pathogenesis of autoimmune diseases, and clarify mechanisms of action of immune-modulating interventions used in therapy or tested in clinical trials.  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-22-070.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-22-070.html</a> (U19) <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-22-071.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-22-071.html</a> (UM1)	Dependent upon proposal and award mechanism, for up to 5 years	Letter of intent: 4/19/23 Proposal: 5/19/23
		<b>BIOTECHNOLOGY AND BIOMANUFACTURING (4)</b>		
6.	RFI: Bespoke GMP Manufacturing of AAV gene therapy products for the Accelerating Medicines Partnership® (AMP®) Bespoke Gene Therapy Consortium (FNIH)  2022-BGTC-006	The overall goal for this RFI is to obtain information from interested manufacturers with the capability to meet the criteria defined herein, in the event that contract manufacturing services are needed to meet the needs of the BGTC's clinical program. Responding to this RFI is a pre-requisite for any future RFPs for manufacturing services. There is an associated <a href="https://fnih.org/sites/default/files/2022-12/AMP%20BGTC%20AAV%20Gene%20Therapy%20Manufacturer%20Survey%20FINAL.pdf">survey for manufacturers</a> . <a href="https://fnih.org/sites/default/files/2022-12/AMP%20BGTC%20AAV%20Gene%20Therapy%20Manufacturer%20Survey%20FINAL.pdf">https://fnih.org/sites/default/files/2022-12/AMP%20BGTC%20AAV%20Gene%20Therapy%20Manufacturer%20Survey%20FINAL.pdf</a>	N/A	Response: 1/24/23
7.	RFI: National Biotechnology and Biomanufacturing Initiative (OSTP)	This RFI seeks public input on how advances in biotechnology and biomanufacturing can help us achieve goals that were previously out of reach and what steps can be taken to ensure we have the right research ecosystem, workforce, data, domestic biomanufacturing capacity, and other components to support a strong bioeconomy.  <a href="https://www.federalregister.gov/documents/2022/12/20/2022-27600/request-for-information-national-biotechnology-and-biomanufacturing-initiative">https://www.federalregister.gov/documents/2022/12/20/2022-27600/request-for-information-national-biotechnology-and-biomanufacturing-initiative</a>	N/A	Response: 1/20/23



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>BIOTECHNOLOGY AND BIOMANUFACTURING</b>		
8.	RFI: Identifying Ambiguities, Gaps, Inefficiencies, and Uncertainties in the Coordinated Framework for the Regulation of Biotechnology (OSTP)	The White House Office of Science and Technology Policy requests relevant data and information, including case studies, that may assist in identifying any regulatory ambiguities, gaps, inefficiencies, or uncertainties in the Coordinated Framework for the Regulation of Biotechnology, particularly with regard to new and emerging biotechnology products. The information provided will inform regulatory agency efforts to improve the clarity and efficiency of the regulatory processes for biotechnology products. <a href="https://www.federalregister.gov/documents/2022/12/20/2022-27599/request-for-information-identifying-ambiguities-gaps-inefficiencies-and-uncertainties-in-the">https://www.federalregister.gov/documents/2022/12/20/2022-27599/request-for-information-identifying-ambiguities-gaps-inefficiencies-and-uncertainties-in-the</a>	N/A	Response: 2/3/23
9.	BioMADE Project Call: Climate Change (DoD/BioMADE)	BioMADE is now accepting submissions for projects that address research and development priorities that will have a direct impact on mitigating the causes and consequences of global climate change. Priority funding areas include: Sustainable food production; Converting waste to bioproducts; Carbon capture technologies; Lowering the resource requirements for processing steps; Mitigating the impact of climate change. <a href="https://www.biomade.org/news/project-call-climate-change">https://www.biomade.org/news/project-call-climate-change</a>	Up to \$2 million, for up to 2 years Cash-sharing required	Concept: 2/1/23 Must be BioMADE member by 2/15/23 Proposal: 3/1/23
		<b>CANCER (22)</b>		
10.	NCI Small Grants Program for Cancer Research for Years 2023, 2024, and 2025 (NCI Omnibus) (R03 Clinical Trial Optional) (NIH/NCI)  PAR-23-058	This FOA supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-23-058.html">https://grants.nih.gov/grants/guide/pa-files/PAR-23-058.html</a>	Up to \$50,000 per year, for up to 2 years	Proposal: 2/22/23
11.	Pre-Announcement: FY23 Breast Cancer Research Program (BCRP) (DoD/CDMRP)	The FY23 BCRP Program anticipates six awards: Breakthrough Award; Era of Hope Scholar Award; Innovator Award; Clinical Research Extension Award; Transformative Breast Cancer Consortium Award; and Transformative Breast Cancer Consortium Development Award. All applications must address one or more of the program's overarching challenges. <a href="https://cdmrp.health.mil/pubs/press/2023/23bcrrpreann">https://cdmrp.health.mil/pubs/press/2023/23bcrrpreann</a>	Up to \$15 million, for up to 4 years Dependent upon proposal and award mechanism	TBD



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>CANCER</b>		
12.	National Cancer Institute Program Project Applications for the Years 2023, 2024, and 2025 (Po1 Clinical Trial Optional) (NIH/NCI)  PAR-23-059	Through this FOA, the NCI invites multidisciplinary coordinated research programs in any of the broad areas of cancer research, including studies of cancer biology, cancer prevention, cancer diagnosis, cancer treatment, and cancer control. Basic, translational, clinical, and/or population-based studies in all of these research areas are appropriate. The objective of the Program Project is to support an integrated, collaborative research Program with a well-defined, central research focus or objective.  <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-23-059.html">https://grants.nih.gov/grants/guide/pa-files/PAR-23-059.html</a>	Dependent upon proposal, for up to 5 years	Letter of intent: 4/25/23 Proposal: 5/25/23
13.	Co-infection and Cancer (R01/R21 Clinical Trial Not Allowed) (NIH/NCI)  PAR-23-055 (R01) PAR-23-056 (R21)	These FOAs intend to enhance mechanistic and epidemiologic investigations addressing the roles of co-infection and cancer to shed light on presently unestablished pathways in carcinogenesis that may inform prevention and treatment strategies for infection-related cancers.  <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-23-055.html">https://grants.nih.gov/grants/guide/pa-files/PAR-23-055.html</a> (R01) <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-23-056.html">https://grants.nih.gov/grants/guide/pa-files/PAR-23-056.html</a> (R21)	Dependent upon proposal, for up to 5 years (R01) Up to \$275,000, for up to 2 years (R21)	Letter of intent: 1/5/23 Proposal: 2/5/23 (R01) Letter of intent: 1/16/23 Proposal: 2/16/23 (R21)
14.	Applied Regulatory Science Research to Understand Factors that Affect the Safety and Efficacy of Underrepresented Populations in Oncology Therapeutic Development (U01) Clinical Trial Optional (FDA/OC)  RFA-FD-23-006	The purpose of this FOA is to support research that can improve collection of information about underrepresented minorities to increase understanding of the safety and efficacy of oncology therapeutics in populations that have been historically underrepresented in oncology trials, including racial/ethnic minorities, sex and gender minorities, and older adults.  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-23-006.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-23-006.html</a>	Up to \$500,000 per year, for up to 5 years	Letter of intent: 1/6/23 Proposal: 2/22/23
15.	Informatics Technologies for Cancer Research and Management (R21/U01/U24 Clinical Trial Optional) (NIH/NCI)  RFA-CA-23-014 (R21) RFA-CA-23-015 (U01) RFA-CA-23-016 (U24) RFA-CA-23-017 (U24)	These FOAs invite applications for the development, enhancement, and sustainment of informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research.  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-23-014.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-23-014.html</a> (R21) <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-23-015.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-23-015.html</a> (U01) <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-23-016.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-23-016.html</a> (U24) <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-23-017.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-23-017.html</a> (U24)	Up to \$275,000, for up to 2 years (R21) Up to \$300,000 per year, for up to 3 years (U01) Dependent upon proposal, for up to 5 years (U24)	Letter of intent: 5/13/23 Proposal: 6/13/23





	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>CANCER</b>		
16.	PREVENT Cancer Preclinical Drug Development Program (NIH/NCI) <a href="#">75N91023R00024</a>	The overall objective of the current acquisition, designated as the PREVENT Cancer Preclinical Drug Development Program, is to provide a structured approach to drug and vaccine development, from discovery to the clinic. This acquisition is broken into three separate IDIQ pools: PREVENT Efficacy Pool; PREVENT CGMP Pool; PREVENT Toxicology and Pharmacology Pool. <a href="https://sam.gov/opp/b6bb012d59694a46b584dba6a4e4a3d7/view">https://sam.gov/opp/b6bb012d59694a46b584dba6a4e4a3d7/view</a>	Dependent upon proposal	Proposal: 2/21/23
17.	Pre-Announcement: FY23 Ovarian Cancer Research Program (DoD/CDMRP)	Applications to one of the six awards in the FY23 OCRP must address one or more of the following Areas of Emphasis: Understand the basic biology and etiology of ovarian cancer initiation, progression, metastasis, recurrence, genetics, proteogenomics and other critical events; Develop novel therapeutic strategies for treatment and prevention; Identify and develop new strategies for screening, early-stage detection, prevention, accurate diagnosis, and prognosis; Identify and implement strategies to improve the survivorship and quality of life; Address health disparities; Improve precision medicine. <a href="https://cdmrp.health.mil/pubs/press/2023/23ocrppreann">https://cdmrp.health.mil/pubs/press/2023/23ocrppreann</a>	Up to \$2 million, for up to 4 years Dependent upon award mechanism	TBD
		<b>CENTRAL NERVOUS SYSTEM (1)</b>		
18.	NOSI: Efficacy Trials of Epidural Stimulation for Spinal Cord Injury (NIH/NINDS) <a href="#">NOT-NS-23-038</a>	The objective of this NOSI is to encourage investigators with epidural stimulation clinical trials that are ready for this next step to submit to PAR-21-237 for the 02/09/2023 deadline. <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-NS-23-038.html">https://grants.nih.gov/grants/guide/notice-files/NOT-NS-23-038.html</a>	Dependent upon proposal, for up to 5 years	Proposal: 2/9/23
		<b>COGNITIVE AND BRAIN HEALTH (5)</b>		
19.	Pilot, Early, and Late Stage Clinical Trials for the Spectrum of AD/ABDR and Age-Related Cognitive Decline (R01/R61 Clinical Trial Optional) (NIH/NIA) <a href="#">PAR-23-081 (R01)</a> <a href="#">PAR-23-083 (R61)</a>	These FOAs invite applications that enable the collection of pilot data or propose to develop and implement early to late stage clinical trials of pharmacological and non-pharmacological interventions for cognitive and neuropsychiatric changes associated with AD/ABDR across the spectrum from pre-symptomatic to more severe stages, and stimulate studies to enhance trial design and methods. <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-23-081.html">https://grants.nih.gov/grants/guide/pa-files/PAR-23-081.html</a> (R01) <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-23-083.html">https://grants.nih.gov/grants/guide/pa-files/PAR-23-083.html</a> (R61)	Dependent upon proposal, for up to 5 years (R01) Up to \$325,000 per year, for up to 2 years (R61)	Proposal: 2/5/23 (R01) Proposal: 2/17/23 (R61)
20.	BRAIN Initiative: Brain Behavior Quantification and Synchronization (R61/R33 Clinical Trial Optional) (NIH) <a href="#">RFA-MH-23-335</a>	This FOA supports the development and validation of next-generation tools, methods, and analytic approaches to precisely quantify behaviors and combine them with simultaneous recordings of brain activity in humans. <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-23-335.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-23-335.html</a>	Dependent upon proposal, for up to 5 years	Letter of intent: 1/17/23 Proposal: 2/17/23



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>COGNITIVE AND BRAIN HEALTH</b>		
21.	BRAIN Initiative: Transformative Brain Non-invasive Imaging Technology Development (UG3/UH3 Clinical Trial Not Allowed) (NIH)  RFA-EB-22-003	This FOA solicits applications for team-centric development and validation of innovative non-invasive imaging technologies that could have a transformative impact on the study of brain function/connectivity. <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-EB-22-003.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-EB-22-003.html</a>	Up to \$300,000 per year, for up to 3 years (UG3) Up to \$750,000 per year, for up to 4 years (UH3)	Letter of intent: 9/13/23 Proposal: 10/13/23
22.	Tools and resources to understand the vascular pathophysiology of in vivo neuroimaging findings in TBI-related dementia and/or VCID (U24 - Clinical Trials Not Allowed) (NIH/NINDS/NIA)  RFA-NS-23-002	This FOA promotes the development and distribution of innovative technologies, methods, protocols, and biomedical materials that enhance combined human neuropathology and neuroimaging research with data aimed at understanding the underlying pathophysiology of in vivo imaging results typically associated with vascular contributions to cognitive impairment and dementia (VCID) in TBI-related dementia and other AD/DRD diagnoses. <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-23-002.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-23-002.html</a>	Up to \$1 million per year, for up to 5 years	Proposal: 3/17/23
		<b>COMMUNICATION DISORDERS (10)</b>		
23.	NOSI: Fundamental Science Research on the Neural Circuits Underlying Sensory Processing (NIH/NIDCD)  NOT-DC-23-001	NIDCD encourages multidisciplinary and innovative projects, from diverse teams, to advance a mechanistic understanding of the behavior of neural circuits at cellular and sub-second temporal resolution by integrating cutting-edge technologies and approaches for recording and modulation of cells and circuits. <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-DC-23-001.html">https://grants.nih.gov/grants/guide/notice-files/NOT-DC-23-001.html</a>	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 1/8/26
		<b>CORONAVIRUS (7)</b>		
24.	NOSI: Advance Data Science Approaches Through Secondary Data Analysis to Reveal Scientific Insights of COVID-19 Testing Technologies (R21) (NIH)  NOT-OD-23-040	The research objective of this NOSI is to stimulate data science approaches by catalyzing the scientific value and revealing scientific insights through secondary analysis of existing data collected from the RADx programs. The research topic areas may include, but are not limited to, biomedical, clinical, social, ethical, and behavioral issues. <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-OD-23-040.html">https://grants.nih.gov/grants/guide/notice-files/NOT-OD-23-040.html</a>	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 5/30/23





	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>CORONAVIRUS</b>		
25.	NOSI: Promoting Research on COVID-19 and Rheumatic, Musculoskeletal and Skin Diseases (NIH/NIAMS)  NOT-AR-23-008	In line with overall NIH efforts, NIAMS would like to promote basic, translational, pre-clinical and clinical observational research focused on COVID-19 infection and its intersection with rheumatic, musculoskeletal, and skin diseases and conditions. <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-AR-23-008.html">https://grants.nih.gov/grants/guide/notice-files/NOT-AR-23-008.html</a>	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 1/7/24
		<b>ENDOCRINE AND METABOLIC DISEASES (1)</b>		
26.	Pilot and Feasibility Trials on the Integration of Social and Medical Care for Type 1 Diabetes Mellitus (R01 Clinical Trial Required) (NIH/NIDDK)  RFA-DK-22-028	This FOA supports pilot and feasibility trials to test pragmatic interventions that include screening for adverse social determinants of health (SDoH) and referring or providing resource service linkages for social services within the healthcare setting for individuals living with type 1 diabetes. <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-22-028.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-22-028.html</a>	Up to \$350,000 per year, for up to 3 years	Letter of intent: 6/20/23 Proposal: 7/20/23
		<b>GENOMICS (2)</b>		
27.	Genomic Community Resources (U24 Clinical Trial Not Allowed) (NIH)  PAR-23-085	Awards under this FOA will support both new and existing genomic resources of broad value to the research community. The major goal of this FOA is to provide access to these genomic resources by the research community; data and resource dissemination should be a major component of these awards.  <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-23-085.html">https://grants.nih.gov/grants/guide/pa-files/PAR-23-085.html</a>	Dependent upon proposal, for up to 5 years	Proposal: 1/25/23
28.	Ancillary Studies to the NIDDK Inflammatory Bowel Disease Genetics Consortium (R01 Clinical Trial Not Allowed) (NIH/NIDDK)  RFA-DK-22-023	The purpose of this FOA is to expand the number of IBD susceptibility loci, causal variants and effector genes, and IBD-related phenotypes and physiological domains under investigation via Ancillary Studies utilizing the extensive resources, including subjects, samples and datasets, established by the IBDGC. <a href="https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-22-023.html">https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-22-023.html</a>	Up to \$300,000 per year, for up to 4 years	Letter of intent: 2/9/23 Proposal: 3/9/23
		<b>HEALTH IT (32)</b>		
29.	Supporting the use of Real-World Data to Generate Real-World Evidence in Regulatory Decision-Making (U01) CT Optional (FDA/CBER)  RFA-FD-23-025	The primary objectives of this announcement are to a) improve the quality and/or use of RWD, b) promote better understanding of RWE study designs, and c) develop specific tools to evaluate aspects of RWE generation. <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-23-025.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-23-025.html</a>	Up to \$2.25 million per year, for up to 3 years	Proposal: 2/28/23



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>HEALTH IT</b>		
30.	NOSI: Optimization of Data Storage and Utilization for the Sequence Read Archive (SRA) (NIH)  NOT-GM-23-015	The SRA contains a broad collection of raw DNA and RNA sequence data and alignment information that continues to grow exponentially. This NOSI encourages grant applications focused on efficiency optimization and cost reduction for SRA data storage and utilization. <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-GM-23-015.html">https://grants.nih.gov/grants/guide/notice-files/NOT-GM-23-015.html</a>	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 12/18/25
31.	Technology Integration to Optimize Military Health and Performance (MTEC)  MTEC-23-03-Performance	The objective of this RPP is to identify an organization able to serve as an “integrator” proficient at leveraging the capabilities of an existing network of performers to advance materiel and knowledge products that improve the physical, cognitive, and psychological health and performance of Service Members (SM). The goal is to create an actively coordinated “mini-consortium” program that incorporates organizations dedicated to researching, developing, testing/evaluating, and manufacturing human health and performance products. <a href="https://mtec-sc.org/wp-content/uploads/2023/01/MTEC-23-03-Performance_RPP.pdf">https://mtec-sc.org/wp-content/uploads/2023/01/MTEC-23-03-Performance_RPP.pdf</a>	Up to \$6.7 million per year, for up to 3 years	Enhanced white paper due: 2/10/23
32.	Biomedical Knowledgebase and Data Repository (U24 - Clinical Trials Not Allowed) (NIH)  PAR-23-078 PAR-23-079	These FOAs are designed to support biomedical knowledge bases and data repositories. Biomedical data repositories accept submission of relevant data from the community to store, organize, validate, archive, preserve and distribute the data, in compliance with the FAIR Data Principles. Biomedical knowledgebases on the other hand extract, accumulate, organize, annotate, and link the growing body of information that is related to and relies on core datasets. <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-23-078.html">https://grants.nih.gov/grants/guide/pa-files/PAR-23-078.html</a> <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-23-079.html">https://grants.nih.gov/grants/guide/pa-files/PAR-23-079.html</a>	Dependent upon proposal, for up to 5 years	Proposal: 1/25/23
33.	NOSI: BRAIN Initiative: Developing Data Archive, Informatics Tools and Data Standards for Brain Behavior Quantification and Synchronization (BBQS) (NIH)  NOT-MH-23-115	This NOSI supports a) creation of data archive(s) to store and manage BBQS-relevant data; b) development of computational tools or software for analyzing, visualizing and integrating BBQS-related data, and for predicting and modeling the complex dynamics of the brain-behavior system; and c) establishment of data standards or ontologies that support the BBQS-related studies. <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-MH-23-115.html">https://grants.nih.gov/grants/guide/notice-files/NOT-MH-23-115.html</a>	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 7/14/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>HEALTH IT</b>		
34.	Emerging Mathematics in Biology (eMB) (NSF)  NSF 23-537	The eMB program seeks to stimulate fundamental interdisciplinary and potentially transformative research pertaining to the development of innovative mathematical/statistical/computational theories, tools, and modeling approaches to investigate challenging questions of great interest to biologists and public health policymakers. Research examples include: modeling tools for emerging infectious diseases, neuroscience, applications of foundational mathematics in genomics. <a href="https://www.nsf.gov/pubs/2023/nsf23537/nsf23537.htm">https://www.nsf.gov/pubs/2023/nsf23537/nsf23537.htm</a>	Up to \$6 million per year, for up to 3 years	Proposal: 3/22/23
35.	Small Research Grants for Analyses of Gabriella Miller Kids First Pediatric Research Data (R03 Clinical Trial Not Allowed) (NIH)  PAR-23-075	This FOA is intended to support meritorious small research projects focused on analyses of childhood cancer and/or structural birth defects genomic datasets generated by the Kids First program and/or associated phenotypic datasets. Development of approaches, tools, or algorithms appropriate for analyzing genomic, phenotypic, and/or clinical data relevant to Kids First may also be proposed. <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-23-075.html">https://grants.nih.gov/grants/guide/pa-files/PAR-23-075.html</a>	Up to \$200,000, for up to 2 years	Proposal: 2/16/23
36.	Enhancing the Use of the All of Us Research Program's Data (R21/R03 Clinical Trial Not Allowed) (NIH)  RFA-PM-23-001 (R21) RFA-PM-23-002 (R03)	The All of Us Research Program encourages investigators to apply for grant awards that will advance research in high-priority mission areas of the ICOs through two companion FOAs (1) one to use standard methods and approaches to analyze currently available data within the All of Us Research Program's Researcher Workbench and (2) one to develop new methods, models, and tools and use them to analyze data in the Researcher Workbench. <a href="https://grants.nih.gov/grants/guide/rfa-files/rfa-pm-23-001.html">https://grants.nih.gov/grants/guide/rfa-files/rfa-pm-23-001.html</a> (R21) <a href="https://grants.nih.gov/grants/guide/rfa-files/rfa-pm-23-002.html">https://grants.nih.gov/grants/guide/rfa-files/rfa-pm-23-002.html</a> (R03)	Up to \$275,000, for up to 2 years (R21) Up to \$200,000, for up to 2 years (R03) Dependent upon award mechanism	Letter of intent: 1/30/23 Proposal: 3/1/23
37.	Archiving and Documenting Child Health and Human Development Data Sets (R03 Clinical Trial Not Allowed) (NIH/NICHD)  PAR-22-261	The purpose of this FOA is to support the archiving and documentation of existing data sets within the scientific mission of the NICHD to facilitate secondary analysis of these data by the scientific community. The highest priority is to facilitate the sharing of original data collected with NICHD funding. <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-22-261.html">https://grants.nih.gov/grants/guide/pa-files/PAR-22-261.html</a>	Up to \$50,000 per year, for up to 2 years	Letter of intent: 1/16/23 Proposal: 2/16/23



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>HIV/AIDS (2)</b>		
38.	<p>Mechanisms and Targets at the Intersection of HIV and Substance Use (R01/R21 Clinical Trials Not Allowed) (NIH/NIDA)</p> <p>RFA-DA-24-013 (R01) RFA-DA-24-014 (R21)</p>	<p>These FOAs support research on the discovery and development of novel chemical and biological approaches to prevent and/or treat CNS complications associated with HIV infection and substance use. NIDA is specifically interested in supporting basic research on signaling pathways, virus-host protein interactions, and post-translational protein modifications.</p> <p><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-013.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-013.html</a> (R01)  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-014.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-014.html</a> (R21)</p>	<p>Up to \$400,000 per year, for up to 5 years (R01) Up to \$275,000, for up to 2 years (R21)</p>	<p>Letter of intent: 7/9/23 Proposal: 8/9/23</p>
		<b>IMMUNOLOGY &amp; INFECTIOUS DISEASE (4)</b>		
39.	<p>Cellular Immunology Core Laboratory (NIH/NIAID)</p> <p>75N93022R00029</p>	<p>The purpose of the CICL is to conduct, analyze, develop, optimize, and validate cellular immunologic assays for HIV, Simian Immunodeficiency Virus (SIV), Mycobacterium tuberculosis (Mtb), and other pathogens, performed on fresh and frozen preclinical samples. All assays undergo testing for inter- and intra-assay as well as inter- and intra-operator variability. Standard operating procedures (SOPs) are developed for equipment use and maintenance, laboratory processes, and all assays.</p> <p><a href="https://sam.gov/opp/4c583d70b3f046eb889062567ce92e48/view">https://sam.gov/opp/4c583d70b3f046eb889062567ce92e48/view</a></p>	<p>Dependent upon contract</p>	<p>Proposal: 3/17/23</p>
40.	<p>Vaccine Adjuvant Discovery Program (NIH/NIAID)</p> <p>BAA-DAIT-75N93022R00022</p>	<p>This BAA supports the identification and characterization of novel, effective and safe vaccine adjuvants. The process of discovery new adjuvants through this program must include each of the following areas of research: (1) Identification of novel adjuvant candidates using high throughput (HTS) approaches and validation that lead compounds stimulate human cells; (2) determination of the mechanism of action of select lead compounds; (3) optimization of lead adjuvant candidates through formulation and medicinal chemistry, guided by structure-activity relationship (SAR) studies; and (4) verification of the efficacy of lead compounds as vaccine adjuvants in vivo in an animal model.</p> <p><a href="https://sam.gov/opp/467138fb7ee34914838455bad76f011f/view">https://sam.gov/opp/467138fb7ee34914838455bad76f011f/view</a></p>	<p>Dependent upon proposal and award mechanism</p>	<p>Proposal: 5/19/23</p>
41.	<p>Pre-Clinical Models of Infectious Diseases (NIH/NIAID)</p> <p>NIHAI75N93023R00003</p>	<p>The current NIAID Preclinical Models of Infectious Diseases IDIQ contract program is one of DMID's preclinical services resources and supports the development and refinement of animal models and animal replacement models of infectious diseases, models that subsequently are used to evaluate candidate medical countermeasures against these diseases. This program serves the DMID mission of supporting investigator-initiated research by providing critical data needed to apply for grant or other funding.</p> <p><a href="https://sam.gov/opp/323f55a8f5434c78b2e7e0eod767681e/view">https://sam.gov/opp/323f55a8f5434c78b2e7e0eod767681e/view</a></p>	<p>Dependent upon contract</p>	<p>Proposal: 2/28/23</p>



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>IMMUNOLOGY &amp; INFECTIOUS DISEASE</b>		
42.	CDC FY23 Broad Agency Announcement (HHS/CDC) <a href="#">75D301-23-R-72545</a>	This BAA will support contracts relating to many topics of research interest to the CDC. Vector-borne diseases, antibiotic resistance, and respiratory illnesses including COVID-19 are included. <a href="https://sam.gov/opp/15229982f7c348f69fd35e9a0add8aba/view">https://sam.gov/opp/15229982f7c348f69fd35e9a0add8aba/view</a>	Dependent upon proposal and award mechanism	White paper: 2/3/23
		<b>MATERNAL AND PEDIATRIC HEALTH (1)</b>		
43.	Partnering Research and Community Organizations for Novel Health Equity Research: Addressing Social and Clinical Determinants of Maternal Health – Cycle 1 2023 (PCORI)	Applicants must address the following research question: What is the comparative effectiveness of multicomponent, multilevel interventions to improve maternal outcomes for individuals from populations highly impacted by maternal health disparities? Proposed CER studies may focus on pre-and/or postnatal care and should include at least one of each of the following types of interventions: Health systems strategies to address disparities in maternal health outcomes and Strategies to address social determinants of health. <a href="https://www.pcori.org/funding-opportunities/announcement/partnering-research-and-community-organizations-novel-health-equity-research-addressing-social-and-clinical-determinants-maternal-health-cycle-1-2023">https://www.pcori.org/funding-opportunities/announcement/partnering-research-and-community-organizations-novel-health-equity-research-addressing-social-and-clinical-determinants-maternal-health-cycle-1-2023</a>	Up to \$20 million, for up to 5 years Dependent upon proposal and award mechanism	Letter of intent: 2/7/23 Proposal: 5/2/23
		<b>MENTAL HEALTH (8)</b>		
44.	Clinical Studies of Mental Illness (Collaborative R01) (CT Optional) (NIH/NIMH) <a href="#">PAR-23-050</a>	This FOA seeks to support collaborative clinical studies, that primarily focus on mental health genetics, biomarker studies, and studies of mental illnesses. Applicants should apply to this FOA when two or more sites are needed to complete the study. <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-23-050.html">https://grants.nih.gov/grants/guide/pa-files/PAR-23-050.html</a>	Dependent upon proposal, for up to 5 years	Letter of intent: 1/5/23 Proposal: 2/5/23
45.	Bidirectional Influences Between Adolescent Social Media Use and Mental Health (R01/R21 Clinical Trial Optional) (NIH/NIMH) <a href="#">RFA-MH-23-115 (R01)</a> <a href="#">RFA-MH-23-116 (R21)</a>	These FOAs encourage applications that focus on understanding bidirectional relationships between social media use and adolescent mental health, psychiatric symptoms, and risk or resilience for psychopathology. <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-23-115.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-23-115.html</a> (R01) <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-23-116.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-23-116.html</a> (R21)	Dependent upon proposal, for up to 5 years (R01) Up to \$275,000, for up to 2 years (R21)	Letter of intent: 2/24/23 Proposal: 3/24/23
46.	Building in vivo Preclinical Assays of Circuit Engagement for Application in Therapeutic Development (R01 CT Not Allowed) (NIH/NIMH) <a href="#">PAR-23-091</a>	This FOA will support efforts to optimize and evaluate measures of neurophysiological and behavioral processes that may serve as pharmacokinetic/pharmacodynamic (PK/PD) markers of neural processes of clinical interest based on available knowledge of the neurobiology of mental illnesses. <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-23-091.html">https://grants.nih.gov/grants/guide/pa-files/PAR-23-091.html</a>	Dependent upon proposal, for up to 5 years	Letter of intent: 5/5/23 Proposal: 6/5/23





	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>MENTAL HEALTH</b>		
47.	Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R01 Clinical Trial Optional) (NIH/NIMH)  PAR-23-093	This FOA encourages applications to pursue invasive neural recording studies focused on mental health-relevant questions. Invasive neural recordings provide an unparalleled window into the human brain to explore the neural circuitry and neural dynamics underlying complex moods, emotions, cognitive functions, and behaviors with high spatial and temporal resolution. This FOA aims to target a gap in the scientific knowledge of neural circuit function related to mental health disorders. <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-23-093.html">https://grants.nih.gov/grants/guide/pa-files/PAR-23-093.html</a>	Dependent upon proposal, for up to 5 years	Letter of intent: 5/5/23 Proposal: 6/5/23
48.	Innovative Mental Health Services Research Not Involving Clinical Trials (R01 Clinical Trials Not Allowed) (NIH/NIMH)  PAR-23-095	This FOA encourages innovative research that will inform and support the delivery of high-quality, continuously improving mental health services to benefit the greatest number of individuals with, or at risk for developing, a mental illness. <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-23-095.html">https://grants.nih.gov/grants/guide/pa-files/PAR-23-095.html</a>	Dependent upon proposal, for up to 5 years	Letter of intent: 5/5/23 Proposal: 6/5/23
49.	Laboratories to Optimize Digital Health (R01 Clinical Trial Required) (NIH/NIMH)  PAR-23-096	This FOA is intended to support the development of digital health test beds that leverage well-established digital mental health platforms and infrastructure to rapidly refine and optimize existing evidence-based digital health interventions and to conduct clinical research testing digital mental health interventions that are statistically powered to provide a definitive answer regarding the intervention's effectiveness particularly in populations who experience health disparities and vulnerable populations. <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-23-096.html">https://grants.nih.gov/grants/guide/pa-files/PAR-23-096.html</a>	Dependent upon proposal, for up to 4 years	Letter of intent: 5/5/23 Proposal: 6/5/23
50.	Mood and Psychosis Symptoms during the Menopause Transition (R01 Clinical Trial Optional) (NIH/NIMH)  PAR-23-097	This FOA encourages applications that will advance mechanistic and translational research on the onset and worsening of mood and psychotic disorders during the menopausal transition. <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-23-097.html">https://grants.nih.gov/grants/guide/pa-files/PAR-23-097.html</a>	Dependent upon proposal, for up to 5 years	Proposal: 2/5/23
		<b>MUSCULOSKELETAL HEALTH (1)</b>		
51.	Solutions to Accelerate Return-to-Readiness following Musculoskeletal Injuries (MTEC)  MTEC-23-02-MSKI	The overall objective of effort is to identify and enable the development of solutions to accelerate recovery following acute or cumulative musculoskeletal injury. Prototypes may include developing medical technologies and treatments or rehabilitative strategies for musculoskeletal injuries. <a href="https://mtec-sc.org/wp-content/uploads/2023/01/MTEC-23-02-MSKI_RPP_Final.pdf">https://mtec-sc.org/wp-content/uploads/2023/01/MTEC-23-02-MSKI_RPP_Final.pdf</a>	Up to \$1.47 million, for up to 3 years	Enhanced white paper due: 2/28/23



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>PATIENT-CENTERED RESEARCH (5)</b>		
52.	Broad Pragmatic Studies Funding Announcement -- 2023 Standing PFA (PCORI)	This PFA invites applications for high-quality comparative clinical effectiveness research projects. Applicants have the option to choose up to three of <a href="https://www.pcori.org/funding-opportunities/announcement/broad-pragmatic-studies-funding-announcement-2023-standing-pfa">eight topic themes</a> , based on how their proposed research aligns with the themes. <a href="https://www.pcori.org/funding-opportunities/announcement/broad-pragmatic-studies-funding-announcement-2023-standing-pfa">https://www.pcori.org/funding-opportunities/announcement/broad-pragmatic-studies-funding-announcement-2023-standing-pfa</a>	Up to \$10 million, for up to 5 years Dependent upon award mechanism	Letter of intent: 2/7/23 Proposal: 5/2/23
53.	Improving Methods for Conducting Patient-Centered Outcomes Research -- 2023 Standing PFA (PCORI)	For this PFA, PCORI has identified the following areas as programmatic priorities: Methods to Improve the Use of AI and ML in Clinical Research; Methods to Improve Study Design; Methods to Support Data Research Networks; Methods Related to Ethical and Human Subjects Protections Issues in PCOR/CER. <a href="https://www.pcori.org/funding-opportunities/announcement/improving-methods-conducting-patient-centered-outcomes-research-2023-standing-pfa">https://www.pcori.org/funding-opportunities/announcement/improving-methods-conducting-patient-centered-outcomes-research-2023-standing-pfa</a>	Up to \$750,000, for up to 3 years	Letter of intent: 2/7/23 Proposal: 5/2/23
54.	Implementation of Effective Shared Decision Making Approaches in Practice Settings -- Cycle 1 2023 (PCORI)	This initiative will support projects that propose active, multi-component approaches to implementing effective shared decision making strategies that address existing barriers and obstacles to uptake and maintenance. The SDM strategy must have demonstrated effectiveness on patient, caregiver, or healthcare provider decision making using widely accepted metrics; the corresponding implementation approach must have potential for use and scalability beyond the targeted implementation setting. <a href="https://www.pcori.org/funding-opportunities/announcement/implementation-effective-shared-decision-making-approaches-practice-settings-pfa-cycle-1-2023">https://www.pcori.org/funding-opportunities/announcement/implementation-effective-shared-decision-making-approaches-practice-settings-pfa-cycle-1-2023</a>	Up to \$1.5 million, for up to 3 years	Letter of intent: 2/7/23 Proposal: 5/2/23
55.	Open Competition PFA: Implementation of Findings from PCORI's Major Research Investments -- Cycle 1 2023 (PCORI)	For the Cycle 1 2023 PFA, PCORI has identified the following four areas of eligible evidence: Obesity Treatment in Primary Care Settings; Nonsurgical treatment options can improve or eliminate symptoms for women with urinary incontinence (UI); Several kinds of therapy and medicines can reduce or stop symptoms for people with PTSD; The use of narrow-spectrum versus broad-spectrum antibiotics to treat children's acute respiratory tract infections (ARTIs). <a href="https://www.pcori.org/funding-opportunities/announcement/open-competition-pfa-implementation-findings-pcoris-research-investments-cycle-1-2023">https://www.pcori.org/funding-opportunities/announcement/open-competition-pfa-implementation-findings-pcoris-research-investments-cycle-1-2023</a>	Up to \$2.5 million, for up to 3 years	Letter of intent: 2/7/23 Proposal: 5/2/23
56.	Advancing the Science of Engagement PCORI Funding Announcement -- Cycle 1 2023 (PCORI)	This PFA will fund studies that build an evidence base on engagement in research, including: Measures to capture structure/context, process, and outcomes; Techniques that lead to effective engagement; How these techniques should be modified and resourced for different contexts, settings, and communities to ensure equity; How engagement supports successful research. <a href="https://www.pcori.org/funding-opportunities/announcement/advancing-science-engagement-pcori-funding-announcement-cycle-1-2023">https://www.pcori.org/funding-opportunities/announcement/advancing-science-engagement-pcori-funding-announcement-cycle-1-2023</a>	Up to \$1.5 million, for up to 3 years	Letter of intent: 2/7/23 Proposal: 5/2/23



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>RECONSTRUCTIVE TRANSPLANT (1)</b>		
57.	FY22 Reconstructive Transplant Research Program Clinical Network Award (DoD/CDMRP)  HT9425-23-RTRP-CAN	The RTRP seeks vascularized composite allotransplantation (VCA)-focused research. Applicants must address the standardization and assessment of protocols and/or clinical practice guidelines (CPGs) for all of the RTRP Focus Areas for both face and hand transplantation. <a href="https://cdmrp.health.mil/funding/pa/HT9425-23-RTRP-CNA-GG2.pdf">https://cdmrp.health.mil/funding/pa/HT9425-23-RTRP-CNA-GG2.pdf</a>	Up to \$10 million, for up to 4 years Resource sharing required	Pre-Application: 1/18/23 Proposal: 2/1/23
		<b>REGENERATIVE MEDICINE (1)</b>		
58.	Pre-Announcement: The Armed Forces Institute for Regenerative Medicine (AFIRM) (MTEC)	This RPP will support a goal/product-driven consortium of universities, companies, military laboratories, and investigators to accelerate development of regenerative medicine therapies. The Coordinating Site for the AFIRM Consortium will translate regenerative medicine technologies related to Warfighter needs from early-stage development to transition to the Warfighter and the commercial marketplace. <a href="https://www.mtec-sc.org/solicitations/#Upcoming-Solicitations">https://www.mtec-sc.org/solicitations/#Upcoming-Solicitations</a>	Up to \$19.1 million for FY2023; additional funds may be available, for up to 5 years	TBD
		<b>RESEARCH RESOURCES (1)</b>		
59.	Animal and Biological Material Resource Centers (P40) (Clinical Trials Not-Allowed) (NIH/ORIP)  RFA-OD-23-001	This FOA encourages grant applications for Animal and Biological Material Resource Centers. These Centers provide support for special colonies of laboratory animals, as well as other resources such as informatics tools, reagents, cultures (cells, tissues, and organs) and genetic stocks that serve the biomedical research community in a variety of research areas on a local, regional, and national basis. <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-23-001.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-23-001.html</a>	Dependent upon proposal, for up to 5 years	Proposal: 2/21/23
		<b>SUBSTANCE USE DISORDER (23)</b>		
60.	Brief Interventions for Adolescent Alcohol Use -- Cycle 1 2023 (PCORI)	Despite the widespread endorsement of screening and brief interventions for adolescent substance use and the emerging evidence base for this population, questions remain about optimal parameters for content, delivery, and follow-up for brief interventions. PCORI's Targeted PFA is soliciting applications that respond to the following question: What is the comparative effectiveness of brief behavioral interventions, adapted for adolescents ages 12-17, to address alcohol use? PCORI is particularly interested in studies comparing primary care or school-based interventions adapted to increase reach, engagement, and/or effectiveness for adolescents. PCORI is also interested in studies comparing brief interventions tailored to historically excluded, underresearched, and/or underresourced adolescent populations. <a href="https://www.pcori.org/funding-opportunities/announcement/brief-interventions-adolescent-alcohol-use-targeted-pfa-cycle-1-2023">https://www.pcori.org/funding-opportunities/announcement/brief-interventions-adolescent-alcohol-use-targeted-pfa-cycle-1-2023</a>	Up to \$5 million, for up to 5 years	Letter of intent: 2/7/23 Proposal: 5/2/23



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>SUBSTANCE USE DISORDER</b>		
61.	Rapid Translation of Epidemiological Findings into Interventions to Prevent Substance Use and Addiction (R61/R33 CT Optional)(NIH/NIDA)  RFA-DA-24-010	This FOA supports research led by multidisciplinary teams to advance translation of epidemiological research into interventions to prevent substance use and addiction. <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-010.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-010.html</a>	Up to \$500,000 per year, for up to 5 years	Letter of intent: 2/15/23 Proposal: 3/15/23
62.	NOSI: Targeting the Endocannabinoid System (ECS) for Brain Health and Acute and Chronic Diseases (NIH)  NOT-DA-22-048	This NOSI encourages studies of the ECS and its roles in brain health and acute and chronic disease, substance use, and SUD. The desired outcomes of research will be a mechanistic understanding of how cannabinoids and manipulation of the ECS can elicit both therapeutic and deleterious effects as well as the role of cannabinoids and ECS in symptom management. <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-DA-22-048.html">https://grants.nih.gov/grants/guide/notice-files/NOT-DA-22-048.html</a>	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 1/8/26
		<b>THERAPEUTICS (2)</b>		
63.	Translational Centers for Microphysiological Systems (TraCe MPS) (U2C Clinical Trials Not Allowed) (NIH/FDA)  RFA-TR-23-001	This FOA aims to establish Centers to support research that will accelerate the translational use of Microphysiological Systems (MPS) in drug development through regulatory acceptance and adoption for industrial use, by establishing MPS that are fit-for-purpose for industry needs and have specific defined contexts of use (CoUs) and will be developed with consideration of applicable expectations to achieve regulatory approval. <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-23-001.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-23-001.html</a>	Dependent upon proposal, for up to 5 years	Letter of intent: 2/26/23 Proposal: 3/27/23
64.	Development and Validation of a Multi-functional, Multi-purpose Quantitative Tool for Dermal PBPK Modeling (U01) Clinical Trial Optional (FDA/CDER)  RFA-FD-23-015	The purpose of this FOA is to develop and validate an enhanced mechanistic PBPK model to reliably describe the skin permeation of active pharmaceutical ingredients in topical drug products applied on the skin surface of virtual subjects by accounting for the drug product quality attributes and the metamorphosis these products undergo post application. <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-23-015.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-23-015.html</a>	Up to \$250,000 per year, for up to 3 years	Letter of intent: 1/23/23 Proposal: 3/20/23
		<b>TUBEROUS SCLEROSIS COMPLEX (3)</b>		
65.	Pre-Announcement: FY23 Tuberous Sclerosis Complex Research Program (DoD/CDMRP)	Applications to the three awards in the FY23 TSCRCP must address one or more Focus Areas: Understanding, preventing, and treating the features of TSC-Associated Neuropsychiatric Disorders; Strategies for eradicating tumors associated with TSC and TSC-associated lymphangi leiomyomatosis; Preventing, epilepsy, improving treatment, and mitigating neurodevelopmental and adverse outcomes associated with TSC-related seizures; Developing, assessing, and testing emerging technologies to improve outcomes in TSC. <a href="https://cdmrp.health.mil/pubs/press/2023/23tscrppreann">https://cdmrp.health.mil/pubs/press/2023/23tscrppreann</a>	Up to \$1.15 million, for up to 3 years Dependent upon award mechanism	TBD



## Recurring Opportunities

January 10, 2023

<https://www.g2gconsulting.com/gbg-reporting-service/>

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>AIR FORCE (4)</b>		
66.	Airman Readiness Medical Research (ARMR) Hybrid BAA  <a href="#">FA8650-20-S-6008</a>	The Warfighter Medical Optimization Division intends to solicit White Papers under this announcement with the focus of conducting medical research in support of optimizing of the warfighter by enabling, enhancing, restoring, and sustaining the Airman to more effectively execute the Air Force mission. This medical research objective is dual natured: (1) ensure medical availability of Airmen by analyzing attributes (sensory, behavioral, physiologic) and operational environments (chemical, physical, psychological, biological, radiological stressors) to drive optimal performance of Airmen engaged in high-demand, high-impact mission tasks (2) investigate how the flight environment affects the process of life, the ability to maintain homeostasis, and the risk for injury or secondary insult, seeking to ameliorate these stressors to optimize Airman health and performance. <a href="https://www.grants.gov/web/grants/view-opportunity.html?oppld=327332">https://www.grants.gov/web/grants/view-opportunity.html?oppld=327332</a>	Up to \$49 million, per award	White papers accepted on rolling basis until 4/30/26
67.	Air Force Office of Scientific Research Broad Agency Announcement  <a href="#">FA9550-18-S-0003</a>	This BAA's focus is on research areas that offer significant and comprehensive benefits to national warfighting and peacekeeping capabilities. These areas are organized and managed in two scientific branches: Engineering and Information Sciences (RTA) and Physical and Biological Sciences (RTB). Research topics in the Chemistry and Biological sciences categories include Biophysics; Human Performance and Biosystems; Mechanics of Multifunctional Materials and Microsystems; Molecular Dynamics and Theoretical Chemistry; Natural Materials, Systems, and Extremophiles; and Organic Materials Chemistry. <a href="https://www.grants.gov/web/grants/view-opportunity.html?oppld=305996">https://www.grants.gov/web/grants/view-opportunity.html?oppld=305996</a>	Dependent upon proposal	Proposals accepted on a rolling basis



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>AIR FORCE</b>		
68.	Research Interests of the Air Force Office of Scientific Research  FA9550-21-S-0001	The focus of AFOSR is on research areas that offer significant and comprehensive benefits to our national war fighting and peacekeeping capabilities. The Engineering and Complex Systems team leads the discovery and development of the fundamental and integrated science that advances future air and space flight. The Information and Networks Team is organized to support many U.S. Air Force and Space Force priority areas including autonomy, space situational awareness, and cyber security. The Physical Sciences Team leads the discovery and transition of foundational physical science to enable air, space, and cyber power. The Chemistry and Biological Sciences Team is responsible for research activities in fundamental chemistry, biology, mechanics, and biophysics research. <a href="https://www.grants.gov/web/grants/view-opportunity.html?oppld=334084">https://www.grants.gov/web/grants/view-opportunity.html?oppld=334084</a>	Dependent upon proposal, for up to 5 years	White papers accepted on a rolling basis
69.	Research Interests of the United States Air Force Academy  USAFA-BAA-2021	USAFA invites white papers and proposals for research in many broad areas, under the direction of several research centers. One such center, is the Life Sciences Research Center (LSRC). LSRC intrigued by biomaterials found in nature, which use unique biologic design principles and processes to form novel structures. The USAF requires lighter, tougher materials, which can hold up under extreme temperature, pressure or loading conditions. <a href="https://www.grants.gov/web/grants/view-opportunity.html?oppld=330175">https://www.grants.gov/web/grants/view-opportunity.html?oppld=330175</a>	Dependent upon proposal, for up to 5 years	Proposals accepted on a rolling basis
		<b>ARMY (8)</b>		
70.	BAA R&D in Support of the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND), JPM Medical and JPL EB  CBRND-BAA-22-01	The JPMO is interested in studies on new and better ways to develop medical CBRN countermeasures more rapidly and with increased efficiency through enabling technologies, life cycle bioinformatics, and improved logistics tracking. Mission areas include: Biological Medical Prophylaxis; Medical, Chemical, and Biological Countermeasures; Medical Radiological Countermeasures; Medical Diagnostic and Surveillance Systems; and Enabling Biotechnologies and Response Systems. <a href="https://sam.gov/opp/66870bda25274773b3e5fa7cfd3coe11/view">https://sam.gov/opp/66870bda25274773b3e5fa7cfd3coe11/view</a>	Dependent upon proposal	Proposals accepted on a rolling basis through 6/11/27
71.	USAMRDC Broad Agency Announcement for Extramural Medical Research  HT9425-23-S-BAA1	R&D funded by this BAA are expected to benefit and inform both military and civilian medical practice and knowledge. Research areas include: Military Infectious Disease; Combat Casualty Care; Military Operational Medicine; Medical Biological Defense; and Medical Chemical Defense. <a href="https://www.grants.gov/web/grants/view-opportunity.html?oppld=343725">https://www.grants.gov/web/grants/view-opportunity.html?oppld=343725</a>	Dependent upon proposal, for up to 5 years	Pre-applications accepted until 9/30/27 Full proposal by invitation



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>ARMY</b>		
72.	USSOCOM BAA for Extramural Biomedical Research and Development  <a href="#">W81XWH-18-S-SOC1</a>	A primary emphasis of the USSOCOM Biomedical, Human Performance, and Canine Research Program is to identify and develop techniques, knowledge products, and materiel for early intervention in life-threatening injuries, prolonged field care, human performance optimization, and canine medicine/performance. Special Operations Forces (SOF) medical personnel place a premium on medical equipment that is small, lightweight, ruggedized, modular, multi-use, and designed for operation in extreme environments.  <a href="https://www.grants.gov/web/grants/view-opportunity.html?oppld=307754">https://www.grants.gov/web/grants/view-opportunity.html?oppld=307754</a>	Dependent upon proposal	Proposals accepted through 7/31/23 Submission of a pre-proposal is required
73.	Army Research Office Broad Agency Announcement for Fundamental Research  <a href="#">W911NF-23-S-0001</a>	ARL's foundational research mission spans basic research and applied research but may include advanced technology development and advanced component development and prototypes when opportunities arise to directly or indirectly help achieve ARL's mission. Topics include Biotronics, Genetics, and Neurophysiology of Cognition; the full list of research topics is available here:  <a href="https://www.arl.army.mil/opportunities/arl-baa/">https://www.arl.army.mil/opportunities/arl-baa/</a> <a href="https://sam.gov/opp/72a66224611942dd9215e60722caaac5/view">https://sam.gov/opp/72a66224611942dd9215e60722caaac5/view</a>	Dependent upon proposal	Proposals accepted on a rolling basis until 11/20/27
74.	Army Research Institute for the Behavioral and Social Sciences Broad Agency Announcement for Basic, Applied, and Advanced Research  <a href="#">W911NF-18-S-0005</a>	ARI seeks Applied Research proposals that provide a systematic expansion and application of knowledge to design and develop useful strategies, techniques, methods, tests, or measures that provide the means to meet a recognized and specific Army need. Applied Research precedes specific technology investigations or development and should have high potential to transition into advanced technology.  <a href="https://www.grants.gov/web/grants/view-opportunity.html?oppld=304462">https://www.grants.gov/web/grants/view-opportunity.html?oppld=304462</a>	Dependent upon proposal	Proposals accepted on a rolling basis until 4/29/23 Full proposal required
75.	Army Applications Lab BAA for Disruptive Applications  <a href="#">W911NF-19-S-0004</a>	AAL is interested in any and all technologies which can be shown to enable the Army of 2028 to be ready to deploy, fight, and win decisively against any adversary, anytime, and anywhere, in a joint, multi- domain, high-intensity conflict, while simultaneously deterring others and maintaining its ability to conduct irregular warfare.  <a href="https://www.grants.gov/web/grants/view-opportunity.html?oppld=315517">https://www.grants.gov/web/grants/view-opportunity.html?oppld=315517</a>	Dependent upon proposal	Proposals accepted through 5/1/24 Pre-proposal is required
76.	Army Research Office Broad Agency Announcement Staff Research Program  <a href="#">W911NF20S0003</a>	The purpose of the program is to enable ARO scientific staff to maintain and expand professional competence in support of fulfilling the ARO mission through the conduct of hands-on, basic research. Research efforts will involve scientific study directed toward advancing the state-of-the-art or increasing knowledge and scientific understanding in engineering, physical, life and information sciences.  <a href="https://www.arl.army.mil/wp-content/uploads/2020/04/arl-baa-Staff-Research-PA.pdf">https://www.arl.army.mil/wp-content/uploads/2020/04/arl-baa-Staff-Research-PA.pdf</a>	Dependent upon proposal	Proposals accepted on a rolling basis until 2/19/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>ARMY</b>		
77.	Army Combat Capabilities Development Command Broad Agency Announcement <a href="#">W911QY20R0022</a>	Broad Agency Announcement Solicitation for the US Army Combat Capabilities Development Command - Soldier Center (CCDC-SC). Please see the BAA solicitation document for the submission instructions and areas of interest. <a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=327285">https://www.grants.gov/web/grants/view-opportunity.html?oppId=327285</a>	Dependent upon proposal	Proposals accepted on a rolling basis until 2/28/25
		<b>BARDA (2)</b>		
78.	BARDA Broad Agency Announcement <a href="#">BARDABAA</a>	BARDA is accepting proposals related to diagnostics and POC tests for COVID and other MCM topics that include: CBRN Vaccines, Antivirals & Antitoxins; Antibacterials; Radiological, Nuclear & Chemical Threat MCMs; Burn Medical MCMs; Diagnostics; Influenza & Emerging Diseases vaccines and therapeutics. <a href="https://sam.gov/opp/550c21c541ac4c5ea14a52997a84a65d/view">https://sam.gov/opp/550c21c541ac4c5ea14a52997a84a65d/view</a> <a href="https://www.medicalcountermeasures.gov/barda/barda-baa">https://www.medicalcountermeasures.gov/barda/barda-baa</a>	Dependent upon proposal	White papers: 3/17/23
79.	BARDA DRIVe EZ-BAA <a href="#">EZBAA-22-100-SOL-00003</a>	BARDA is currently accepting submissions through the EZ-BAA for several AOIs: AOI #15: ReDIRECT; AOI #16: Lab at Home; AOI #17: Digital MCMs; AOI #18: Host-Directed Therapeutics; AOI #19: Healing Lungs; AOI #20: DRIVe Forward ; AOI #21: Vaccines on Demand; AOI #22: ReBoot; AOI #23: Host-Based Diagnostics; AOI #24: Repurposing and Advancing Innovations Against Rad/Nuc Threats (REPAIR). <a href="https://sam.gov/opp/c24b8eba795743b9a0194a078163d04f/view">https://sam.gov/opp/c24b8eba795743b9a0194a078163d04f/view</a>	Up to \$750,000 per award	Proposals accepted on a rolling basis Deadlines vary by AOI
		<b>DARPA (3)</b>		
80.	Biological Technologies BAA <a href="#">HR001122S0034</a>	BTO's research investment portfolio includes combating pandemic disease, innovative physiological interventions, human performance and warfighter readiness, and deep exploration of changing ecologies and environments for improving U.S. capabilities and resilience. BTO is interested in submissions related to the following topic areas: Human Performance, Materials, Sensors, Processing, Biosecurity, Biomedical, and Biodefense <a href="https://sam.gov/opp/df93a5637fc419a8ea392ee949f9c79/view">https://sam.gov/opp/df93a5637fc419a8ea392ee949f9c79/view</a>	Dependent upon proposal	Abstracts & proposals accepted on a rolling basis until 4/20/23
81.	Redefining Possible - 2022 <a href="#">HR001122S0040</a>	The Tactical Technology Office (TTO) of DARPA is soliciting executive summaries, proposal abstracts, and proposals for applied research, advanced technology development, platform demonstrations, or systems studies that aim to redefine the future of warfighting across four domains: Air, Ground, Maritime, and Space. <a href="https://sam.gov/opp/a517e20d661b431aa933e55263a2bc42/view">https://sam.gov/opp/a517e20d661b431aa933e55263a2bc42/view</a>	Up to \$1 million, for up to 18 months	Proposals accepted on a rolling basis until 6/21/23
82.	Defense Sciences Office, Office-wide <a href="#">HR001122S0041</a>	The DSO Office-wide BAA invites proposers to submit innovative basic or applied research concepts or studies and analysis proposals that address one or more of the following technical thrust areas: Novel Materials & Structures; Sensing and Measurement; Computation and Processing; Enabling Operations; Collective Intelligence; and Global Change. <a href="https://sam.gov/opp/d99f59e0d48245e688b92af595380c79/view">https://sam.gov/opp/d99f59e0d48245e688b92af595380c79/view</a>	Dependent upon proposal	Abstracts accepted on a rolling basis until 6/14/23



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>DEFENSE THREAT REDUCTION AGENCY (2)</b>		
83.	Fundamental Research to Counter Weapons of Mass Destruction (C-WMD)  HDTRA1-14-24-FRCWMD-BAA	DTRA seeks to identify, adopt, and adapt emerging, existing and revolutionary sciences that may demonstrate high payoff potential to Counter-WMD (C-WMD) threats. Current thrust areas include global biosurveillance, biosafety, and biosecurity, and chemical and biological defense. <a href="https://sam.gov/opp/da2d0850923340169b5263998efe73f6/view">https://sam.gov/opp/da2d0850923340169b5263998efe73f6/view</a>	Up to \$1 million per year, for up to 5 years	White papers accepted through 9/2024
84.	Research and Development Innovations Broad Agency Announcement  HDTRA1-22-S-0003	DTRA seeks proposals that will advance research, development, test, and evaluation (RDT&E) priorities across three interrelated thrust areas derived from the 2019 DTRA Strategic Plan for RDT&E (plan available at <a href="https://www.dtra.mil/">https://www.dtra.mil/</a> ): <ul style="list-style-type: none"> <li>• Understand the environment, threats, and vulnerabilities</li> <li>• Control, defeat, disable, and dispose of threats</li> <li>• Safeguard the force and manage consequences</li> </ul> <a href="https://sam.gov/opp/98f9fec4443f4e5d988d2680d85c97fo/view">https://sam.gov/opp/98f9fec4443f4e5d988d2680d85c97fo/view</a>	Dependent upon proposal, for up to 18 months	White papers accepted on a rolling basis through 2/14/27
		<b>DEPARTMENT OF ENERGY (1)</b>		
85.	FY2023 Continuation of Solicitation for the Office of Science Financial Assistance Program  DE-FOA-0002844	By integrating genome science with advanced computational and experimental approaches, the Division seeks to gain a predictive understanding of living systems, from microbes and microbial communities to plants and ecosystems. This foundational knowledge enables design and reengineering of microbes and plants underpinning a broad clean energy and bioeconomy portfolio. <a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=343866">https://www.grants.gov/web/grants/view-opportunity.html?oppId=343866</a>	Dependent upon award mechanism	Proposals accepted on a rolling basis through 9/30/23
		<b>NATIONAL SCIENCE FOUNDATION (1)</b>		
86.	Small Business Innovation Research Program Phase I (SBIR/STTR Phase I)  NSF 23-515	The NSF SBIR and STTR programs focus on transforming scientific discovery into products and services with commercial potential and/or societal benefit. Unlike fundamental or basic research activities that focus on scientific and engineering discovery itself, the NSF SBIR program supports the creation of opportunities to move fundamental science and engineering out of the lab and into the market or other use at scale, or startups and small businesses representing “deep technology ventures.” The programs fund research and development, and are designed to provide non-dilutive funding and entrepreneurial support at the earliest stages of company and technology development. The required Project Pitch allows startups and small businesses to get quick feedback at the start of their application for Phase I funding. <a href="#">Click here</a> for project pitch details and for the full list of topics <a href="#">click here</a> . <a href="https://www.nsf.gov/pubs/2023/nsf23515/nsf23515.htm">https://www.nsf.gov/pubs/2023/nsf23515/nsf23515.htm</a>	Up to \$275,000 for up to 1 year	<a href="#">Project pitches</a> accepted on a rolling basis. Submission window for invited proposals: 11/22/22 to 3/1/23



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>NAVY (3)</b>		
87.	Long Range Broad Agency Announcement for Navy and Marine Corps Science and Technology  N00014-23-S-B001	The ONR, ONR Global, and Marine Corps Warfighting Lab are interested in receiving proposals for Long-Range S&T Projects which offer potential for advancement and improvement of Navy and Marine Corps operations. <a href="https://www.nre.navy.mil/work-with-us/funding-opportunities/fy23-long-range-broad-agency-announcement-baa-navy-and-marine">https://www.nre.navy.mil/work-with-us/funding-opportunities/fy23-long-range-broad-agency-announcement-baa-navy-and-marine</a>	Dependent upon proposal	Proposals accepted on a rolling basis until 9/30/23
88.	NRL Long Range Broad Agency Announcement (BAA) for Basic and Applied Research  N00173-23-S-BA01	The Naval Research Laboratory is seeking to advance technology developed for in vitro diagnostic devices that are amenable to military hardening and integration with communication capabilities to support the medical diagnostic and epidemiological detection and biosurveillance needs of the US military across multiple Echelons of Care and specifically for field deployment at Echelons 1 or 2. <a href="https://sam.gov/opp/58eeca6ef84a4d25b41boedaca42447a/view">https://sam.gov/opp/58eeca6ef84a4d25b41boedaca42447a/view</a>	Dependent upon proposal and award mechanism	White papers accepted through 9/30/23
89.	Broad Agency Announcement for Innovative Environmental Technologies and Methodologies  N3943022S2401	This announcement seeks out technologies and methodologies to reduce environmental impacts from current and past Navy operations, and applies to Navy installations worldwide. NEXWC is interested in environmental technologies and methodologies that are either new, innovative, advance the state-of-the art, or increase knowledge or understanding of a technology or methodology. <a href="https://sam.gov/opp/31a0cb3fe2fc4777b2f723ebe37a7d59/view">https://sam.gov/opp/31a0cb3fe2fc4777b2f723ebe37a7d59/view</a>	Dependent upon proposal	Abstracts accepted on a rolling basis until 3/21/23

